Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Euromedis Groupe (ALEMG.PA)
Mouy, FR
Euromedis Groupe, a French company established in 1985 and based in Mouy, France, specializes in the development, manufacturing, and distribution of medical equipment. Operating under its proprietary Euromedis brand, the company caters to a broad clientele in France, including medical professionals, local public services, and private individuals. Its extensive product line encompasses a wide array of medical supplies. This includes sterile and non-sterile gloves, wound care essentials like dressings and compresses, and various medical kits. For parenteral care, it provides items such as needles, syringes, infusers, and catheters. The surgical range is comprehensive, featuring wound drainage products, probes, draping solutions for operating theaters, surgical gloves, and protective covers. Beyond these, Euromedis also offers oxygen therapy equipment, products for continence management and general hygiene, diagnostic tools, and a selection of home care necessities. In addition to its product offerings, Euromedis Groupe provides services such as the distribution and rental of medical equipment, as well as specialized in-home infusion and nutrition support. While primarily focused on the French market, the company has a significant international footprint, exporting its products to numerous countries including Belgium, Italy, Morocco, Ivory Coast, Gabon, Benin, Algeria, Ireland, the Netherlands, Portugal, Tunisia, Switzerland, the Czech Republic, the United Kingdom, Germany, Finland, Spain, Greece, Hungary, Lithuania, Latvia, Bulgaria, and Poland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.43% | +10.42% | +13.25% | +19.37% | +32.50% | +35.20% | +38.74% | +29.58% | -68.82% | -9.40% | +0.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Devices: +11.2%+12.7% ★ Q4'25: +59.7% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+98.4% ★ Q4'25: -101.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+0.7% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+0.7% Q4'25: +1.8% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+5.1% ★ Q4'25: +15.2% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.9% Q4'25: +0.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×20.36× ★ Q4'25: 1.04× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
71.20M
est: 71.20M (0.0%)
|
73.17M
est: 73.10M (+0.1%)
|
73.60M
est: 73.70M (-0.1%)
|
76.06M
est: 77.70M (-2.1%)
|
77.08M
est: 76.90M (+0.2%)
|
193.41M
est: 159.70M (+21.1%)
|
111.90M
est: 143.40M (-22.0%)
|
54.18M
est: 57.40M (-5.6%)
|
37.43M
est: 31.01M (+20.7%)
|
36.22M
est: 35.74M (+1.3%)
|
40.80M
est: 37.53M (+8.7%)
|
39.40M
39.40M – 39.40M
+5.0% YoY
|
| EBITDA |
4.88M
est: -2.15M (+327.1%)
|
2.93M
est: -2.20M (+232.8%)
|
1.37M
est: -2.22M (+161.5%)
|
-397.4K
est: -2.34M (+83.0%)
|
-1.87M
est: -2.32M (+19.2%)
|
31.00M
est: -4.82M (+743.5%)
|
4.39M
est: -4.33M (+201.5%)
|
-4.51M
est: -1.73M (-160.5%)
|
-4.44M
est: -1.88M (-135.5%)
|
-5.38M
est: -2.17M (-147.8%)
|
300.0K
est: -2.28M (+113.2%)
|
-2.39M
-2.39M – -2.39M
-5.0% YoY
|
| EBIT |
3.40M
est: -3.28M (+203.6%)
|
1.36M
est: -3.37M (+140.3%)
|
-993.0K
est: -3.40M (+70.8%)
|
-2.13M
est: -3.58M (+40.5%)
|
-3.03M
est: -3.54M (+14.6%)
|
29.18M
est: -7.36M (+496.6%)
|
2.89M
est: -6.61M (+143.8%)
|
-5.63M
est: -2.64M (-112.9%)
|
-5.56M
est: -2.32M (-139.7%)
|
-5.60M
est: -2.67M (-109.6%)
|
300.0K
est: -2.81M (+110.7%)
|
-2.95M
-2.95M – -2.95M
-5.0% YoY
|
| Net Income |
2.47M
est: 2.11M (+17.3%)
|
1.01M
est: 2.11M (-52.2%)
|
-146.0K
est: 1.91M (-107.6%)
|
-4.92M
est: 1.14M (-531.7%)
|
-3.80M
est: -975.6K (-289.1%)
|
22.66M
est: 8.63M (+162.5%)
|
2.26M
est: 8.10M (-72.1%)
|
-5.96M
est: -5.88M (-1.2%)
|
13.11M
|
-6.11M
est: 1.17M (-622.5%)
|
-100.0K
est: 1.21M (-108.3%)
|
1.25M
1.25M – 1.25M
+3.6% YoY
|
| SGA |
11.39M
est: 11.82M (-3.6%)
|
11.69M
est: 12.13M (-3.7%)
|
13.63M
est: 12.23M (+11.4%)
|
26.16M
est: 12.90M (+102.8%)
|
13.79M
est: 12.76M (+8.1%)
|
17.04M
est: 26.51M (-35.7%)
|
18.07M
est: 23.80M (-24.1%)
|
25.35M
est: 9.53M (+166.1%)
|
4.21M
est: 4.60M (-8.6%)
|
—
est: 5.30M (-100.0%)
|
—
est: 5.57M (-100.0%)
|
5.85M
5.85M – 5.85M
+5.0% YoY
|
| EPS |
0.85
est: 0.74 (+14.9%)
|
0.34
est: 0.74 (-54.1%)
|
-0.05
est: 0.67 (-107.3%)
|
-1.64
est: 0.40 (-510.0%)
|
-1.27
est: -0.34 (-270.9%)
|
7.53
est: 3.03 (+148.5%)
|
0.75
est: 2.84 (-73.6%)
|
-2.03
est: -2.07 (+1.7%)
|
4.60
|
-2.15
est: 0.41 (-628.5%)
|
-0.03
est: 0.42 (-108.3%)
|
0.44
0.44 – 0.44
+3.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mathieu Roturier | Chairman of the Board of Directors & Chief Executive Officer | 289.5K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALEMG.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
